Ga-FAPI-46 PET/CT
Phase 2Small molecule
Ga-FAPI-46 PET/CT is one of 13 small molecule programs targeting Head and Neck Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Pleural Mesothelioma
#DrugCompanyPhaseTrials
1Alimta
SShawn Eagle
Phase 3
Paraplatin
AAvyxa
Phase 3
Alimta
EEagle Pharmaceuticals, Inc.
Phase 3
Volrustomig
AstraZenecaPhase 3
Keytruda
Merck & Co.Phase 2
Ivonescimab Combined With Chemotherapy
SSun Yat-sen University
Phase 2
Anetumab Ravtansine
BayerPhase 2
Neoadjuvant Therapy 1
TTang-Du Hospital
Phase 2
Ga-FAPI-46 PET/CT
JJohn O. Prior
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pleural Mesothelioma1 trial
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Recruiting·—·Phase 2·NCT06790082·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-FAPI-46 PET/CT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJohn O. Prior